Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Merck Recalls MMR Vaccine

June 22, 2012 10:21 am | News | Comments

Merck & Co. is recalling 39,000 doses of a vaccine against measles, mumps, and rubella because it was shipped before the company finished an internal approval process.


FDA Denies Xarelto Expansion

June 22, 2012 10:17 am | News | Comments

Federal regulators have denied Johnson & Johnson's request to expand approval of Xarelto for a new use preventing life-threatening blood clots in high-risk patients.


Oligonucleotide Synthesis

June 21, 2012 12:01 pm | Product Releases | Comments

Link Technologies Ltd has launched two modified phosphoramidite ranges to complement its existing extensive portfolio of products to support oligonucleotide synthesis.


Size Exclusion Chromatography Column

June 21, 2012 11:56 am | Drug Discovery & Development | Product Releases | Comments

Phenomenex Inc. introduces Yarra—a family of aqueous size exclusion chromatography (SEC) columns for biomolecule analysis.


UHPLC System

June 21, 2012 11:50 am | Drug Discovery & Development | Product Releases | Comments

Thermo Fisher Scientific Inc. has introduced the UltiMate 3000 XRS UHPLC system, offering advanced solvent delivery and sample handling with a range of detector options.


New Ways to Target Prostate Cancer

June 21, 2012 11:40 am | News | Comments

New classes of drugs target the androgens that prostate cancer thrive off in novel ways, providing alternatives to traditional methods that often carry high side effects.


Molecule May Jumpstart Heart Repair

June 21, 2012 11:30 am | News | Comments

Researchers have discovered that a single protein may hold the key to turning cardiac stem cells into blood vessels or muscle tissue.


UW Enrolling for Leukemia Study

June 21, 2012 11:22 am | News | Comments

The University of Washington has begun enrolling patients in a Phase 2 study testing Cell Therapeutics' tosedostat in elderly patients with acute myeloid leukemia.


Huntington's Trial Completes Enrollment

June 21, 2012 11:16 am | News | Comments

Raptor Pharmaceutical Corp. has finished enrollment for its Phase 2/3 clinical trial of RP103 for the potential treatment of Huntington's disease.


Population Genetics Collaborating with Oxford

June 21, 2012 11:10 am | News | Comments

Two research groups are using Population Genetics Technologies to enable studies on gene variants associated with myocardial infarction, diabetes, and metabolic disease.


AstraZeneca Buys Ardea for $1.26B

June 21, 2012 11:00 am | News | Comments

AstraZeneca PLC said that it completed its $1.26 billion acquisition of gout drug developer Ardea Biosciences Inc.


Strong Data Boosts Idenix Treatment

June 21, 2012 10:56 am | News | Comments

Hepatitis C drug developer Idenix Pharmaceuticals Inc. has reported promising results from a mid-stage study of a potential treatment.


No New Trial in Risperdal Case

June 21, 2012 10:53 am | News | Comments

A judge has denied a request for a new trial after he fined Johnson & Johnson and a subsidiary $1.2 billion for downplaying and concealing risks associated with Risperdal.


Panel in Favor of Carfilzomib

June 21, 2012 10:48 am | News | Comments

A panel of cancer specialists endorsed a potential blood cancer treatment from Ligand Pharmaceuticals' development partner, Onyx Pharmaceuticals.


EMD Millipore Launches Provantage Solutions

June 20, 2012 12:09 pm | News | Comments

EMD Millipore has launched Provantage Solutions, process development, manufacturing consulting, and implementation services, provided by EMD Millipore scientists.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.